Vikas Kotagal1,2, Cathie Spino3,4, Nicolaas I Bohnen1,2,3,5, Robert Koeppe5, Roger L Albin1,2,3. 1. Department of Neurology, University of Michigan. 2. Veterans Affairs Ann Arbor Health System. 3. University of Michigan Morris K. Udall Center of Excellence for Parkinson's Disease Research. 4. Department of Biostatistics, School of Public Health, University of Michigan. 5. Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI.
Abstract
OBJECTIVE: Serotoninergic neurotransmission may modulate β-amyloid peptide (Aβ) metabolism through upregulation of α-secretase. Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Aβ deposition. METHODS: We conducted 3 analyses to explore associations between serotoninergic neurotransmission and cerebral Aβ burden in PD. The first was a cross-sectional imaging study of PD subjects (n = 23) using the serotoninergic transporter positron emission tomography (PET) ligand [11 C]3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile (DASB) and amyloid PET Pittsburgh compound B ([11 C]PiB). The second was a baseline study of Parkinson's Progression Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid (CSF) Aβ-42 levels (n = 389), controlling for age, sex, Geriatric Depression Scale, disease duration, and education. Third, we fit an interval censored proportional hazard model with longitudinal PPMI data (n = 367) to test whether serotoninergic medication use associates with reduced risk of PD cognitive decline, defined as time to reach a Montreal Cognitive Assessment score ≤ 20, adjusting for baseline caudate dopamine transporter [123 I]ioflupane single photon emission computed tomography and CSF Aβ-42 levels. RESULTS: Serotoninergic DASB distribution volume ratio (DVR) inversely associated with PiB DVR in the cerebral cortex (Pearson r = -0.478, p = 0.021) but not the striatum (r = -0.264, p = 0.224). In the baseline PPMI analysis, serotoninergic medication use for ≥6 months associated with a lower level of CSF Aβ-42 (t = -2.20, p = 0.029). In the longitudinal PPMI model, baseline serotoninergic medication use associated with a reduced risk of cognitive decline (t = -2.03, p = 0.043) after controlling for covariates. INTERPRETATION: Cortical Aβ burden in PD associates inversely with serotoninergic innervation. Serotoninergic medications may alter Aβ metabolism and reduce the risk of PD cognitive decline. Ann Neurol 2018;83:994-1002.
OBJECTIVE: Serotoninergic neurotransmission may modulate β-amyloid peptide (Aβ) metabolism through upregulation of α-secretase. Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Aβ deposition. METHODS: We conducted 3 analyses to explore associations between serotoninergic neurotransmission and cerebral Aβ burden in PD. The first was a cross-sectional imaging study of PD subjects (n = 23) using the serotoninergic transporter positron emission tomography (PET) ligand [11 C]3-amino-4-(2-dimethylaminomethyl-phenylsulfaryl)-benzonitrile (DASB) and amyloid PET Pittsburgh compound B ([11 C]PiB). The second was a baseline study of Parkinson's Progression Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid (CSF) Aβ-42 levels (n = 389), controlling for age, sex, Geriatric Depression Scale, disease duration, and education. Third, we fit an interval censored proportional hazard model with longitudinal PPMI data (n = 367) to test whether serotoninergic medication use associates with reduced risk of PD cognitive decline, defined as time to reach a Montreal Cognitive Assessment score ≤ 20, adjusting for baseline caudate dopamine transporter [123 I]ioflupane single photon emission computed tomography and CSF Aβ-42 levels. RESULTS: Serotoninergic DASB distribution volume ratio (DVR) inversely associated with PiB DVR in the cerebral cortex (Pearson r = -0.478, p = 0.021) but not the striatum (r = -0.264, p = 0.224). In the baseline PPMI analysis, serotoninergic medication use for ≥6 months associated with a lower level of CSF Aβ-42 (t = -2.20, p = 0.029). In the longitudinal PPMI model, baseline serotoninergic medication use associated with a reduced risk of cognitive decline (t = -2.03, p = 0.043) after controlling for covariates. INTERPRETATION: Cortical Aβ burden in PD associates inversely with serotoninergic innervation. Serotoninergic medications may alter Aβ metabolism and reduce the risk of PD cognitive decline. Ann Neurol 2018;83:994-1002.
Authors: Myria Petrou; Nicolaas I Bohnen; Martijn L T M Müller; Robert A Koeppe; Roger L Albin; Kirk A Frey Journal: Neurology Date: 2012-08-29 Impact factor: 9.910
Authors: Henna Martiskainen; Sanna-Kaisa Herukka; Alena Stančáková; Jussi Paananen; Hilkka Soininen; Johanna Kuusisto; Markku Laakso; Mikko Hiltunen Journal: Ann Neurol Date: 2017-07 Impact factor: 10.422
Authors: Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw Journal: JAMA Neurol Date: 2013-10 Impact factor: 18.302
Authors: Trina Mitchell; Stéphane Lehéricy; Shannon Y Chiu; Antonio P Strafella; A Jon Stoessl; David E Vaillancourt Journal: JAMA Neurol Date: 2021-10-01 Impact factor: 29.907
Authors: Dag Aarsland; Lucia Batzu; Glenda M Halliday; Gert J Geurtsen; Clive Ballard; K Ray Chaudhuri; Daniel Weintraub Journal: Nat Rev Dis Primers Date: 2021-07-01 Impact factor: 52.329
Authors: Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc Journal: Neurotherapeutics Date: 2020-11-17 Impact factor: 6.088